← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	1,039	+44	+4%	$49.9B
2	2 Thermo Fisher Scientific TMO $249B	1,007	+36	+4%	$50.4B
3	3 Novartis NVS $279B	927	+1	+0.1%	$20.2B
4	4 Regeneron Pharmaceuticals REGN $80.1B	577	+14	+2%	$39.7B
5	5 Illumina ILMN $41B	561	-3	-0.5%	$28B
6	6 Agilent Technologies A $49.1B	553	+24	+5%	$11.9B
7	7 Ionis Pharmaceuticals IONS $7.1B	335	+21	+7%	$6.4B
8	8 Revvity RVTY $17B	325	+15	+5%	$5.47B
9	9 Charles River Laboratories CRL $14.4B	268	+10	+4%	$3.62B
10	10 Alnylam Pharmaceuticals ALNY $30B	261	+3	+1%	$6.22B
11	11 Myriad Genetics MYGN $397M	233	-2	-0.9%	$3.88B
12	12 DELISTED bluebird bio BLUE	193	+1	+0.5%	$2.53B
13	13 Bruker BRKR $8.47B	190	+13	+7%	$2.71B
14	14 DELISTED CATALENT, INC. CTLT	188	+12	+7%	$3.11B
15	15 Precigen PGEN $2.64B	180	+7	+4%	$3.09B
16	16 Ultragenyx Pharmaceutical RARE $1.47B	172	+10	+6%	$3.99B
17	ISEE 17 DELISTED IVERIC bio, Inc. Common Stock ISEE	152	+8	+6%	$2.47B
18	18 Sarepta Therapeutics SRPT $1.78B	151	+2	+1%	$1.1B
19	19 Azenta AZTA $1.63B	145	+8	+6%	$671M
20	20 PTC Therapeutics PTCT $4.98B	141	-16	-10%	$1.18B
21	21 DELISTED SANGAMO THERAPEUTICS INC SGMO	141	0	0%	$448M
22	22 Pacific Biosciences PACB $619M	119	+29	+32%	$687M
23	23 Standard BioTools LAB $248M	106	-3	-3%	$306M
24	24 Arrowhead Research ARWR $8.25B	97	-6	-6%	$136M
25	AGTC 25 DELISTED Applied Genetic Technologies Corporation AGTC	88	+28	+47%	$223M